Inventiva (IVA) Deferred Taxes (2021 - 2025)

Inventiva's (IVA) quarterly Deferred Taxes came in at -$646349.0 in Q2 2025, down 756.11% quarter-over-quarter from -$75498.3 in Q4 2022.

Inventiva (IVA) Deferred Taxes (2021 - 2025) Analysis & Trends

Inventiva's Deferred Taxes history runs 3 years deep, the most recent figure standing at -$646349.0 for Q2 2025.

  • On a quarterly basis, Deferred Taxes changed N/A year-over-year to -$646349.0 in Q2 2025; TTM through Jun 2025 was -$773894.5, a N/A change from a year earlier, with the FY2022 full-year figure at -$75498.3, down 399.98% from the prior year.
  • Deferred Taxes slipped to -$646349.0 in Q2 2025 per IVA's latest filing, from -$75498.3 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $25167.4 in Q4 2021 and bottomed at -$646349.0 in Q2 2025.
  • The 3-year median for Deferred Taxes is -$76356.4 (2022), against an average of -$193473.6.
  • Biggest YoY gain for Deferred Taxes was 399.98% in 2022; the steepest drop was 399.98% in 2022.
  • Year by year, Deferred Taxes stood at $25167.4 in 2021, then sank by 399.98% to -$75498.3 in 2022, then tumbled by 756.11% to -$646349.0 in 2025.
  • Per Business Quant, the three latest IVA Deferred Taxes figures stand at -$646349.0 (Q2 2025), -$75498.3 (Q4 2022), and -$77214.5 (Q3 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -188,883.60
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -65.30 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 96.00 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Inventiva 842.48 Mn 842.48 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 -646,348.98
Dec 31, 2022 -75,498.31
Sep 22, 2022 -77,214.53
Dec 31, 2021 25,167.36